Tuesday, 20 October 2009
|
| 08:30 - 10:20 |
Special Session: Recent Lessons From Clinical Trials
|
| 08:30 - 09:00 |
AIDS Vaccine Clinical Evaluation: Where Are We and Where Can We Go?
Gary Nabel, Vacine Research Center, NIH, USA
|
| 09:00 - 09:20 |
Clinical Outcomes from the STEP Study
Susan Buchbinder, HIV Research Section, San Francisco Department of Public Health, USA
|
| 09:20 - 09:40 |
Recent Immunologic Findings from the Step and Related HIV Vaccine Clinical Trials
Nicole Frahm, Fred Hutchinson Cancer Research Center, USA
|
| 09:40 - 10:00 |
Interim Efficacy Analysis of HVTN 503/Phambili: A phase IIB test of concept trial of the MRKAd5 HIV-1 gag/pol/nef vaccine conducted in HIV-1 uninfected adults in South Africa
Glenda Gray, Perinatal HIV Research Unit, South Africa
|
| 10:00 - 10:20 |
Phase III Trial of HIV Prime-Boost Vaccine Combination in Thailand: Result of Final Analysis
Supachai Rerks-Ngarm, Ministry of Health, Thailand |
| 11:00 - 12:30 |
Plenary Session 1: Initiation of the Immune Response
|
| 11:00 - 11:30 |
Innate Control of Adaptive Immunity to Vaccines and Pathogens
Bali Pulendran, Emory Vaccine Center, Emory University, USA
|
| 11:30 - 12:00 |
Harnessing Human Dendritic Cell Subsets for HIV Vaccines
Jacques Banchereau, Baylor Institute for Immunology Research, USA<
|
| 12:00 - 12:30 |
T cell control and viral escape
Phil Goulder, University of Oxford, UK
|
| 12:30 - 14:00 |
Lunch + Poster Session 01
|
| 14:00 - 16:00 |
Symposium 1: Mechanisms of Protection against Transmission and Disease Protection
|
| 14:00 - 14:25 |
Epigenetic control of retroelements
Didier Trono, École Polytechnique Fédérale de Lausanne, Switzerland
|
| 14:25 - 14:50 |
Crosstalk between RNAi and HIV
Monsef Benkirane, Institut de Génétique Humaine, France
|
| 14:50 - 15:15 |
Regulation of Harmful Immune Activation during Non Pathogenic SIVagm Infection in African Green Monkeys
Michaela Müller Trutwin, Institut Pasteur, France
|
| 15:15 - 15:30 |
Phenotypic Analyses of CD8+ T cells that Mediate Virus Inhibition from HIV-1 Vaccinees and HIV-1+ Virus Controllers
Stephanie Freel,Duke University Medical School, USA
|
| 15:30 - 15:45 |
HLA-A*7401 is Associated with Protection from HIV-1 Acquisition and Disease Progression in Mbeya, Tanzania
Rebecca Koehler,US Military HIV Research Program/ Henry M Jackson Foundation, USA
|
| 15:45 - 16:00 |
HIV Specific T Cell Responses and Response Patterns Associated with Viral Control Independent of Classical Non-Progessor HLA class I Alleles
Christian Brander, Irsicaixa AIDS Research Institute, Spain |
| 14:00 - 16:00 |
Symposium 2: Generation of Antibody Responses and Diversity
|
| 14:00 - 14:25 |
Regulation of Broadly Neutralizing Antibody Responses: The Initial B Cell Repertoire To HIV-1 Envelope
Barton Haynes, Duke University Medical Center, USA
|
| 14:25 - 14:50 |
Factors Associated with the Development of HIV Neutralization Breadth
Lynn Morris, National Institute for Communicable Diseases, South Africa
|
| 14:50 - 15:15 |
Eliciting Broad Anti-HIV Neutralizing Antibodies by Vaccination: Lessons Learned from Natural Infection
Leonidas Stamatatos, Seattle Biomedical Research Institute, USA
|
| 15:15 - 15:30 |
A Large-Scale Analysis of Immunoglobulin Sequences Derived From Plasmablasts/Plasma Cells in Acute HIV-1 Infection Subjects
Supriya Munshaw, Duke University, USA
|
| 15:30 - 15:45 |
Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
Mikyung Kim,Dana-Farber Cancer Institute, USA
|
| 15:45 - 16:00 |
Potent and Broad Neutralizing Antibodies from HIV-1 non-Clade B Infected Donor Reveal a New HIV-1 Vaccine Target
Sanjay Phogat, IAVI, USA |
| 16:00 - 17:00 |
Coffee Break + Poster Viewing
|
| 17:00 - 18:30 |
Oral Abstract Session 1: Early Events in Transmission and Infection
|
| 17:00 - 17:15 |
Early events of human immunodeficiency virus type 1 (HIV-1) ex vivo penetration in the foreskin mimicking HIV-1 sexual transmission
Yonatan Ganor, Cochin Institute, France
|
| 17:15 - 17:30 |
Defining the Mechanisms of HIV Entry and Interactions with the Female Genital Tract
Ann Carias, Northwestern University, USA
|
| 17:30 - 17:45 |
Clusterin, a natural ligand of DC-SIGN present in human semen inhibits HIV capture and transmission by dendritic cells
Juan Sabatte, National Reference Center for AIDS, Argentina
|
| 17:45 - 18:00 |
Striking elevations in systemic and mucosal cytokine and chemokine levels in acute HIV-1 infection.
Andrea Stacey,Jenner Institute, University of Oxford, UK
|
| 18:00 - 18:15 |
TLR-mediated pDC responses to HIV-1 ligands
J. Judy Chang, Ragon Institute of MGH, MIT and Harvard, USA
|
| 18:15 - 18:30 |
HIV-1 Plasma RNA Risk of HIV-1 Transmission
Jairam Lingappa, University of Washington, USA
|
| 17:00 - 18:30 |
Oral Abstract Session 2: Vaccine Design
|
| 17:00 - 17:15 |
Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
Bert Jacobs, Arizona State University, USA
|
| 17:15 - 17:30 |
Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV
Frederic Tangy,Institut Pasteur, CNRS, France
|
| 17:30 - 17:45 |
Design and Development of DNA vaccines for the Co-expression of micro-RNA and HIV-1 Env
Adam Wheatley,University of Melbourne, Australia
|
| 17:45 - 18:00 |
HIV-1 gp41 Envelope MPER Mutation Altered Epitope Conformation in Lipid and Increased Sensitivity to 2F5 and 4E10 Neutralizing Antibodies
Xiaoying Shen, Duke University, USA
|
| 18:00 - 18:15 |
Insertion of the HIV-1 gp41 Epitopes 2F5 and 4E10 into the Membrane-Proximal Region of the Vesicular Stomatitis Virus Glycoprotein
Ivo Lorenz,International AIDS Vaccine Initiative, USA
|
| 18:15 - 18:30 |
Recombinant modified Vaccinia Virus Ankara expressing HIV-1 genes activates NK subset capable of controlling HIV infection in vitro
Jean-Saville Cummings, Institut Pasteur, France
|
| 17:00 - 18:30 |
Oral Abstract Session 3: Modulation of the Immune Response to Infection
|
| 17:00 - 17:15 |
HIV-1 infection is characterized by early loss of CD161+ Th17 Cells and Gradual Decline in Regulatory T cells
Andrew Prendergast,University of Oxford, UK
|
| 17:15 - 17:30 |
Regulatory T cells inhibit CD8 T cell proliferation in HIV-1 infection through CD39/Adenosine pathway
Yves Levy, AP-HP, Groupe Henri-Mondor Albert-Chenevier; Universite Paris 12, France
|
| 17:30 - 17:45 |
Increased Regulatory T cell Frequency and HIV-1 Specific Suppression After Therapeutic Vaccination of HIV-Infected Patients on Antiretroviral Therapy
Bernard Macatangay,University of Pittsburgh, USA
|
| 17:45 - 18:00 |
Impairment of HIV-1-specific CD8+ T cell function by soluble epithelial adhesion molecules
Hendrik Streeck, Ragon Institute of MGH, MIT and Harvard, USA
|
| 18:00 - 18:15 |
HIV escape from natural killer cytotoxicity: Nef inhibits NKp44L expression on HIV-infected CD4+ T cells.
Vincent Vieillard,INSERM UMR945, France
|
| 18:15 - 18:30 |
Unique stimulatory properties of myeloid dendrict cells in individuals with "elite" HIV-1 control
Mathias Lichterfeld, Massachusetts General Hospital, USA
|
Wednesday, 21 October 2009
|
| 09:00 – 10:30 |
Plenary Session 2: In Vivo Response to Pathogens and Vaccines
|
| 09:00 - 09:30 |
In Vivo Dynamics of the Immune Response as Revealed by Multiphoton Imaging
Ron Germain, NIAID NIH, USA
|
| 09:30 - 10:00 |
Efficacy of CMV/SIV Vectors
Louis Picker, Vaccine and Gene Therapy Insitute, OHSU, USA
|
| 10:00 - 10:30 |
TB Vaccine Development
Jerald Sadoff, AERAS Global TB Vaccine Foundation, USA
|
| 11:00 - 12:30 |
Oral Abstract Session 4: Update on Clinical Trials
|
| 11:00 - 11:15 |
Safety and Immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: Results of ANRS VAC18, a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Dominique Salmon-Céron, Hôpital Cochin, Université Paris Descartes, France
|
| 11:15 - 11:30 |
Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/ modified Vaccinia virus Ankara (MVA) heterologous boost vaccines
Charlotta Nilsson,Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden
|
| 11:30 - 11:45 |
Characterization of cell-mediated immune responses generated by recombinant Modified Vaccinia Ankara (rMVA)-HIV-1 in a Phase I Vaccine Trial
Jeffrey Currie, Military HIV Research Program, USA
|
| 11:45 - 12:00 |
Perceived parental willingness for their adolescents to participate in future HIV prevention trials: A survey conducted amongst adolescents in Soweto
Kennedy Otwombe,Perinatal HIV Research Unit, South Africa
|
| 12:00 - 12:15 |
Safety and Viral Load changes in HIV-1 Infected Subjects Treated with Autologous Dendritic Immune Therapy following ART discontinuation (CTN#239)
Jean-Pierre Routy,McGill University and INSERM Unit 743, Canada
|
| 12:15 - 12:30 |
Post-infection cellular immune responses in recipients following ALVAC-HIV + AISDVax B/E prime-boost vaccination in the Thai phase III trial
Jerome Kim, Military HIV Research Program, USA
|
| 11:00 - 12:30 |
Oral Abstract Session 5: Novel Vaccinal Approaches
|
| 11:00 - 11:15 |
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers
Sandhya Vasan, Aaron Diamond AIDS Research Center, Rockefeller University, USA
|
| 11:15 - 11:30 |
Analysis of DNA compared to Ad5 vaccination, as single and mixed modalities, demonstrates robust induction of cellular immune responses in macaques
Lauren Hirao,University of Pennsylvania, USA
|
| 11:30 - 11:45 |
Efficacy study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macaques
Frédéric Martinon,CEA / Division of Immuno-Virology, France
|
| 11:45 - 12:00 |
Gp96-Ig-SIV vaccines induce predominant immune responses at mucosal sites
Natasa Strbo, University of Miami Miller School of Medicine, USA
|
| 12:00 - 12:15 |
Impact of in vivo CD4 binding during HIV-1 Env trimer immunizations of rhesus macaques
Iyadh Douagi, Karolinska Institutet, Sweden
|
| 12:15 - 12:30 |
First-in-human phase 1 saftey and immunogenicity of an Adenovirus Serotype 26 HIV-1 vaccine vector
Dan Barouch, Beth Israel Deaconess Medical Center, USA
|
| 11:00 - 12:30 |
Oral Abstract Session 6: Dynamics of HIV Infection and the Immune Response
|
| 11:00 - 11:15 |
Multiplicity of infection by HIV-1 in injection drug users, men who have sex with men and heterosexuals
Katharine Bar,University of Alabama at Birmingham, USA
|
| 11:15 - 11:30 |
Monospecific Expansion of SIVmac251 During Acute Infection Masks Multiple Transmitted Virus Variants Revealed During the Chronic Phase
Barbara Felber,HRPS, VB, NCI-Frederick, USA
|
| 11:30 - 11:45 |
Dynamics of CTL Epitope Escape and Reversion in an African Subtype C cohort
Malinda Schaefer,Emory University, USA
|
| 11:45 - 12:00 |
The Role Of Early T-Cell Responses In Subjects With Acute HIV-1 Infection
Michael Liu, University of Oxford, UK
|
| 12:00 - 12:15 |
Adaptation of HIV-1 to the Human Immune System at the Population Level is Driven by Protective HLA-B Alleles
Ingrid Schellens,University Medical Center Utrecht,Netherlands
|
| 12:15 - 12:30 |
Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial
James Mullins, University of Washington, USA
|
| 12:30 - 14:00 |
Lunch + Poster Session 02
|
| 14:00 - 16:00 |
Symposium 3: Immunological Memory and Protection
|
| 14:00 - 14:25 |
System Biology to Study Immunological Memory during HIV Infection
Elias Haddad, McGill University, Canada
|
| 14:25 - 14:50 |
Correlates of protection to HIV
Alexandre Harari, Centre Hospitalier Universitaire Vaudois, Switzerland
|
| 14:50 - 15:15 |
T Cell Clonotypic Correlates of Virus Control
Daniel Douek, Vaccine Research Center, NIH, USA
|
| 15:15 - 15:30 |
Transitional and Central Memory CD4 T Cells are highly infected in Long Term Non Progressors and Elite Controllers
Benjamin Descours, Université Paris VI UPMC, INSERM UMRs945, France
|
| 15:30 - 15:45 |
A Less Differentiated Memory Phenotype of Gag-Specific CD4+ T-cells during Primary HIV Infection Associates with Viral Control at 12 Months
Pholo Maenetje, National Institutes for Communicable Diseases, South Africa
|
| 15:45 - 16:00 |
Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication
Adam Hersperger, University of Pennsylvania, USA
|
| 14:00 - 16:00 |
Symposium 4: Antigen Presentation and T Cell Epitopes
|
| 14:00 - 14:25 |
Semen clusterin binds DC-SIGN and inhibits HIV-1 capture and transmission by dendritic cells
Sebastian Amigorena, Institut Curie, Paris, France
|
| 14:25 - 14:50 |
Immune recognition of HIV-1 during acute infection
Marcus Altfeld, Ragon Institute of MGH, MIT and Harvard, USA
|
| 14:50 - 15:15 |
Transcriptional control of crosspresentation programs in dendritic cells
Kenneth Murphy, Washington University School of Medicine, USA
|
| 15:15 - 15:30 |
HIV-specific responses induced by anti-CD40 targeting antibodies
Nicolas Loof,INSERM U899-BIIR/INSERM/ANRS Center for Human Vaccines, USA
|
| 15:30 - 15:45 |
The intracellular production of HIV antigenic peptides is guided by predictable motifs and can be altered: implications for immunogen design
Sylvie Le Gall,Harvard Medical School and Mass General Hospital, USA
|
| 15:45 - 16:00 |
Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads
Boris Julg, Ragon Institute of MGH, MIT and Harvard, USA
|
| 16:00 - 17:00 |
Coffee Break + Poster Viewing |
| 17:00 - 18:40 |
Symposium 5: Protection Against Mucosal Transmission and Viral Dissemination
|
| 17:00 - 17:25 |
Characterization of viral variants that initiate systemic infection after mucosal transmission
Eric Hunter, Emory Vaccine Center, USA
|
| 17:25 - 17:50 |
Target Cell Availability and Prevention of Mucosal Transmission
Ashley Haase, University of Minnesota Medical School, USA
|
| 17:50 - 18:15 |
Do Mucosal T-cell Responses Contribute Significantly to HIV Control?
Barbara Shacklett, UC Davis, USA
|
| 18:15 - 18:40 |
Treatment as Prevention
Bernard Hirschel, University Hospital Geneva, Switzerland
|
| 17:00 - 18:40 |
Symposium 6: Refining Immunogen Design
|
| 17:00 - 17:25 |
Structural basis of broad neutralization of HIV-1
Ian Wilson, The Scripps Research Institute, USA
|
| 17:25 - 17:50 |
Primary Immunization Influences the Magnitude, Quality and Breadth of Gag Specific T Cell Responses Following an rAd-5 Boost
Robert Seder, Vaccine Research Center, NIH, USA
|
| 17:50 - 18:15 |
New Applications for Mosaic Antigen Designs
Bette Korber, Los Alamos National Laboratory, USA
|
| 18:15 - 18:40 |
HIV-1 Mosaic Antigens Expand Cellular Immune Breadth and Depth in Rhesus Monkeys
Dan Barouch, Beth Israel Deaconess Medical Centre, Harvard Medical School, USA
|
| 09:00 – 10:30 |
Plenary Session 3: B Cell Biology
|
| 09:00 – 09:30 |
Development of anti-HIV antibodies in humans with high titers of broadly neutralizing antibodies
Michel Nussenzweig, Howard Hughes Medical Institute, The Rockefeller University, USA
|
| 09:30 – 10:00 |
From Antibody to Vaccine – a Tale of Structural Biology and Epitope Scaffolds
Peter Kwong, Vaccine Research Center, NIH, USA
|
| 10:00 - 10:30 |
Induction and Function of the Mucosal Immune System
Per Brandtzaeg, University of Oslo, Norway
|
| 11:00 - 12:00 |
Oral Abstract Session 7: T Cell Responses to Vaccine
|
| 11:00 - 11:15 |
HIV-Specific CD8+ T-Cells of Vaccinees Exhibit Proliferative and Cytotoxic Capacities Comparable to Those of Progressors
Julia Rood, National Institute of Health, USA
|
| 11:15 - 11:30 |
Adenovirus vectors induce expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 infection.
Adel Benlahrech, Imperial College, UK
|
| 11:30 - 11:45 |
Influence of Preexisting Vaccinia Immunity on a DNA/MVA SIV Vaccine, Decreased Cellular Immunity but Enhanced Control of a Pathogenic SIV Challenge
Rama Amara, Yerkes National Primate Center of Emory University, USA
|
| 11:45 - 12:00 |
Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boost vaccination in RV144, the Thai phase III HIV vaccine trial
Mark de Souza, US Military HIV Research Program/AFRIMS, Thailand
|
| 12:00 - 12:50 |
Closing Session
|
| 12:00 - 12:25 |
HIV Vaccinology: What Does the Future Hold?
Anthony Fauci, NIAID, NIH, USA
|
| 12:25 - 12:50 |
Are we targeting the right HIV determinants?
Françoise Barré-Sinoussi, Institut Pasteur, France
|
| 12:50 - 13:00 |
Closing Remarks and Handover
|
| 12:50 - 12:55 |
Yves Levy, ANRS, France |
| 12:55 - 13:00 |
Eric Hunter, Emory Vaccine Center, USA
|
|